PFE vs TMO vs ABBV Stock Comparison

Pfizer, Thermo Fisher Scientific and AbbVie Prices as of Nov 13, 2026 Peers: Industry group
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$166.64B
P/E
41.3x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
4 wins
ABBV AbbVie Inc.
$295.14 +4.1% 1M +27.1% 1Y
Market cap
$527.57B
P/E
51.0x
Revenue (TTM)
$66.01B
Div. yield
–
Pharmaceuticals Healthcare
7 wins

Head to Head

12 decided of 12

AbbVie leads on 7 of the 12 questions below (AbbVie 7, Pfizer 4, Thermo Fisher Scientific 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPFETMOABBVLeader
Larger companyMarket capitalisation $166.64B $255.70B $527.57B ABBV
Cheaper on earningsLower P/E, profitable companies only 41.3x 36.2x 51.0x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 9.8x 27.0x 22.0x PFE
Faster revenue growthRevenue growth, trailing twelve months +1.3% +8.3% +10.7% ABBV
More profitableNet margin, trailing twelve months 6.3% 14.9% 15.7% ABBV
Better return on capitalReturn on invested capital 12.3% 8.0% 24.3% ABBV
Less leveragedLower net debt / EBITDA 1.9x 3.1x 2.4x PFE
Higher dividend yieldTrailing dividend yield 0.06% 0.00% 0.00% PFE
Better 1-year returnPrice return, last 12 months +12.1% +20.7% +27.1% ABBV
Better 5-year returnAnnualised price return, 5 years -10.3%/yr +2.0%/yr +20.3%/yr ABBV
Less volatileAnnualised volatility, 1 year 21.7% 30.7% 25.3% PFE
Higher overall scoreMean of the five percentile scores vs peers 68/100 60/100 70/100 ABBV

Percentile Scorecard

PFETMOABBV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPFETMOABBV
Valuation 95 #37 of 660 62 #94 of 243 90 #68 of 660
Growth 37 #392 of 619 41 #136 of 228 67 #204 of 619
Profitability 92 #50 of 595 82 #40 of 222 96 #23 of 595
Financial Health 25 #516 of 683 31 #172 of 248 15 #580 of 683
Shareholder Returns 91 #44 of 459 82 #29 of 158 81 #89 of 459
Overall 68 60 70
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • ABBV ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPFETMOABBVSPY
1 month -1.1%+4.0%+4.1% -2.0%
3 months +7.9%+19.1%+18.3% -2.8%
6 months +14.1%+59.7%+40.3% +2.0%
Year to date +16.1%+20.8%+29.2% +10.6%
1 year +12.1%+20.7%+27.1% +12.2%
3 years -1.2%+52.5%+113.8% +68.1%
3 years, per year -0.4%+15.1%+28.8% +18.9%
5 years -41.9%+10.2%+152.3% +61.4%
5 years, per year -10.3%+2.0%+20.3% +10.1%
10 years -11.3%+362.9%+367.7% +248.5%
10 years, per year -1.2%+16.6%+16.7% +13.3%

Risk

MeasurePFETMOABBVSPY
Volatility, 1Y 21.7%30.7%25.3% 13.6%
Downside volatility, 1Y 21.9%29.2%24.1% 13.9%
Beta vs S&P 500, 1Y 0.260.71-0.02 1.00
Return / volatility, 1Y 0.560.671.07 0.90
Max drawdown, 5Y -64.8%-41.5%-24.3% -25.4%
From 52-week high -6.1%-3.0%0.0% -3.2%
52-week high $30.79$721.63$295.14 $779.14
52-week low $23.67$438.34$197.38 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePFETMOABBV
P/E now vs peer median 40.8xmedian 17.0x 36.6xmedian 26.5x 50.5xmedian 17.0x
P/S now vs peer median 2.6xmedian 8.4x 5.5xmedian 2.7x 7.9xmedian 8.4x
EV/EBITDA now vs peer median 8.2xmedian 14.6x 25.5xmedian 18.4x 20.4xmedian 14.6x
P/FCF now vs peer median 14.0xmedian 19.0x 34.2xmedian 25.4x 27.6xmedian 19.0x
P/B now vs peer median 1.8xmedian 2.0x 4.7xmedian 2.5x -113.8xmedian 2.0x
PEG now vs peer median -1.47median 0.43 4.84median 0.98 3.03median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPFETMOABBV
Revenue $63.63B $47.35B $66.01B
Gross profit $46.69B $19.45B $48.67B
Operating income $19.40B $8.47B $21.23B
Net income $4.06B $7.09B $10.35B
Free cash flow $11.79B $7.60B $18.87B
R&D $11.52B $1.40B $9.96B
EPS (diluted) $0.70 $19.06 $5.84
Cash & equivalents $1.82B $5.46B $10.77B
Total debt $62.67B $41.37B $80.90B
Shares (diluted) 5.75B 371.00M 1.77B
Enterprise value $114.00B $232.22B $495.58B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPFETMOABBV
P/E 40.8x 36.6x 50.5x
P/FCF 14.0x 34.2x 27.6x
P/Operating cash flow 11.6x 27.8x 26.0x
P/S 2.6x 5.5x 7.9x
P/B 1.8x 4.7x -113.8x
P/Tangible book 3.8x 7.1x -8.5x
EV/EBITDA 8.2x 25.5x 20.4x
EV/EBIT 11.0x 34.8x 27.9x
EV/Revenue 3.3x 6.2x 9.0x
EV/FCF 18.1x 38.8x 31.4x
EV/Operating cash flow 15.0x 31.6x 29.5x
PEG (3Y EPS CAGR) -1.47 4.84 3.03

Growth

14 metrics
MetricPFETMOABBV
Revenue growth (1Y) 1.3% 8.3% 10.7%
Revenue CAGR (3Y) -3.2% 2.9% 6.2%
Gross profit growth (1Y) 1.3% 7.8% 17.0%
Gross profit CAGR (3Y) 2.7% 4.0% 10.3%
Operating income growth (1Y) -4.3% 12.8% 134.9%
Operating income CAGR (3Y) 7.4% 7.2% 12.1%
Net income growth (1Y) -58.9% 7.9% 331.9%
Net income CAGR (3Y) -27.2% 6.2% 16.6%
EPS growth (1Y) -59.2% 9.7% 333.1%
EPS CAGR (3Y) -27.7% 7.6% 16.6%
Operating cash flow growth (1Y) 8.4% 21.9% -3.7%
Operating cash flow CAGR (3Y) 5.6% 4.5% -7.7%
Free cash flow growth (1Y) 13.6% 24.3% -4.1%
Free cash flow CAGR (3Y) 13.0% 5.1% -8.6%

Profitability

14 metrics
MetricPFETMOABBV
Gross margin 73.4% 41.1% 73.7%
EBITDA margin 40.7% 24.4% 43.9%
Operating margin 30.5% 17.9% 32.2%
Pretax margin 6.7% 16.7% 19.4%
Net margin 6.3% 14.9% 15.7%
FCF margin 18.5% 16.0% 28.6%
Operating cash flow margin 22.3% 19.7% 30.4%
Return on equity 4.7% 13.2% –
Return on assets 2.0% 6.2% 7.3%
Return on invested capital 12.3% 8.0% 24.3%
Return on capital employed 11.3% 8.5% 21.6%
Asset turnover 0.3x 0.4x 0.5x
Cash conversion (OCF / net income) 3.5x 1.3x 1.9x
Stock comp / revenue 1.7% 0.7% 1.4%

Financial Health

11 metrics
MetricPFETMOABBV
Debt / assets 30.6% 36.2% 54.8%
Debt / equity 0.7x 0.8x -17.7x
Net debt / EBITDA 1.9x 3.1x 2.4x
Debt / FCF 5.3x 5.4x 4.3x
Liabilities / assets 56.4% 52.1% 103.1%
Equity / assets 43.6% 47.9% -3.1%
Interest coverage – 12.0x –
Current ratio 1.4x 1.8x 0.9x
Quick ratio 0.9x 1.2x 0.6x
Cash ratio 0.4x 0.4x 0.2x
Altman Z-score 2.34 4.18 2.78

Shareholder Returns

7 metrics
MetricPFETMOABBV
Dividend yield 6.0% 0.3% 2.3%
Net buyback yield – 1.6% 0.3%
Shareholder yield 6.0% 1.8% 2.6%
Payout ratio (earnings) 241.2% 9.5% –
Payout ratio (FCF) 83.1% 8.9% –
Dividend growth (1Y) 0.9% 8.0% –
Dividend CAGR (3Y) 2.2% 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPFETMOABBV
Forward P/E 9.8xFY2026 27.0xFY2026 22.0xFY2026
EPS, next fiscal year $2.95FY2026 $25.92FY2026 $13.43FY2026
EPS growth, next FY -8.4%FY2026 +13.3%FY2026 +34.3%FY2026
EPS growth, the year after -5.8% +2.2% +24.3%
Revenue, next fiscal year $61.46BFY2026 $50.12BFY2026 $69.64BFY2026
Revenue growth, next FY -1.8%FY2026 +12.5%FY2026 +13.9%FY2026
Revenue growth, the year after +4.0% -2.7% -0.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPFETMOABBV
Held by institutions 66.9% 90.2% 74.9%
Institutions holding 2,842 2,627 4,183
Change in shares held, QoQ +2.0% +0.8% +2.6%
Institutions buying 1,327 1,145 2,206
Institutions selling 1,206 1,145 1,507
Buyers to sellers 1.10 1.00 1.46

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PFETMOABBV
PFE 1.00 0.24 0.37
TMO 0.24 1.00 0.23
ABBV 0.37 0.23 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PFE, TMO and ABBV?

AbbVie (ABBV) is the largest by market capitalisation: Pfizer (PFE) $166.64B, Thermo Fisher Scientific (TMO) $255.70B, AbbVie (ABBV) $527.57B.

Which stock is cheaper, PFE, TMO and ABBV?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Pfizer (PFE) 41.3x, Thermo Fisher Scientific (TMO) 36.2x, AbbVie (ABBV) 51.0x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Pfizer (PFE) 9.8x, Thermo Fisher Scientific (TMO) 27.0x, AbbVie (ABBV) 22.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

AbbVie (ABBV) grew revenue fastest over the trailing twelve months: Pfizer (PFE) +1.3%, Thermo Fisher Scientific (TMO) +8.3%, AbbVie (ABBV) +10.7%.

Which company is more profitable?

AbbVie (ABBV) has the highest net margin (Pfizer (PFE) 6.3%, Thermo Fisher Scientific (TMO) 14.9%, AbbVie (ABBV) 15.7%). On return on invested capital, AbbVie (ABBV) leads (Pfizer (PFE) 12.3%, Thermo Fisher Scientific (TMO) 8.0%, AbbVie (ABBV) 24.3%).

Which stock has performed better?

Over the past year AbbVie (ABBV) returned the most: Pfizer (PFE) +12.1%, Thermo Fisher Scientific (TMO) +20.7%, AbbVie (ABBV) +27.1%. Over five years, AbbVie (ABBV) compounded fastest (Pfizer (PFE) -10.3%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, AbbVie (ABBV) +20.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Pfizer (PFE) has the highest dividend yield: Pfizer (PFE) 0.06%, Thermo Fisher Scientific (TMO) 0.00%, AbbVie (ABBV) 0.00%. AbbVie (ABBV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Pfizer (PFE) 21.7%, Thermo Fisher Scientific (TMO) 30.7%, AbbVie (ABBV) 25.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PFE, TMO and ABBV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, AbbVie (ABBV) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.